Press coverage about Regulus Therapeutics (NASDAQ:RGLS) has trended somewhat positive this week, Accern Sentiment reports. The research firm identifies positive and negative news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Regulus Therapeutics earned a coverage optimism score of 0.15 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 46.401371189463 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Shares of Regulus Therapeutics (NASDAQ RGLS) traded down 1.50% on Tuesday, reaching $1.31. The company had a trading volume of 134,646 shares. The firm’s market capitalization is $135.96 million. Regulus Therapeutics has a 52 week low of $0.79 and a 52 week high of $3.65. The stock’s 50 day moving average is $1.00 and its 200 day moving average is $1.23.

Regulus Therapeutics (NASDAQ:RGLS) last announced its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.31) by ($0.10). The firm had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.02 million. Regulus Therapeutics had a negative return on equity of 173.20% and a negative net margin of 31,460.47%. On average, equities analysts anticipate that Regulus Therapeutics will post ($1.02) EPS for the current year.

RGLS has been the topic of several analyst reports. Zacks Investment Research upgraded Regulus Therapeutics from a “hold” rating to a “buy” rating and set a $1.25 price objective on the stock in a report on Saturday. Chardan Capital decreased their price objective on Regulus Therapeutics from $5.00 to $2.50 and set a “buy” rating on the stock in a report on Tuesday, June 13th. BMO Capital Markets set a $1.00 price objective on Regulus Therapeutics and gave the stock a “hold” rating in a report on Monday, June 12th. Needham & Company LLC reiterated a “hold” rating on shares of Regulus Therapeutics in a report on Wednesday, August 2nd. Finally, Wedbush reiterated an “ourperform” rating and issued a $4.00 price objective on shares of Regulus Therapeutics in a report on Monday, August 7th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and one has given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $3.63.

ILLEGAL ACTIVITY WARNING: “Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Regulus Therapeutics (RGLS) Share Price” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another site, it was illegally stolen and republished in violation of United States and international trademark & copyright legislation. The original version of this piece of content can be read at https://www.thecerbatgem.com/2017/09/19/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-regulus-therapeutics-rgls-share-price.html.

In related news, Director William H. Rastetter bought 274,725 shares of Regulus Therapeutics stock in a transaction dated Tuesday, July 25th. The shares were acquired at an average cost of $0.91 per share, with a total value of $249,999.75. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Joseph P. Hagan bought 219,780 shares of Regulus Therapeutics stock in a transaction dated Tuesday, July 25th. The shares were bought at an average cost of $0.91 per share, for a total transaction of $199,999.80. Following the completion of the transaction, the insider now owns 241,297 shares of the company’s stock, valued at approximately $219,580.27. The disclosure for this purchase can be found here. Over the last ninety days, insiders have bought 549,450 shares of company stock worth $500,000. Corporate insiders own 4.80% of the company’s stock.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

Insider Buying and Selling by Quarter for Regulus Therapeutics (NASDAQ:RGLS)

Receive News & Stock Ratings for Regulus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics Inc. and related stocks with our FREE daily email newsletter.